Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01776606 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
A Phase 3 study of Skin Aging, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
- 1
- Study location
NCT01776606: Completed Phase 3 study of Skin Aging, sponsored by Revance Therapeutics.
NCT01776606 is a Phase 3 study of Skin Aging that has completed, run by Revance Therapeutics. The registered enrollment target is 247 participants, above the 48-participant average among 9 other Skin Aging trials with a reported enrollment target (415% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01776606, a Phase 3 study of Skin Aging, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Study Locations (1)
Florida
- Dermatology Research Institute - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01776606 record still lists
NCT01776606 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, above the 48-participant average among 9 other Skin Aging trials with a reported enrollment target (415% higher).
The record links to 1 condition, with Skin Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01776606 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01776606 about?
NCT01776606 is a clinical study titled "Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines". This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.
What is the current status of trial NCT01776606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2012-12. Estimated completion is 2013-05.
What conditions does trial NCT01776606 study?
This clinical trial studies the following conditions: Skin Aging.
What interventions are being tested in trial NCT01776606?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT01776606?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01776606 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01776606's enrollment target sits among peer trials
247 1st of 9 higher than 9 of 9 other Skin Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging
ACTIVE NOT RECRUITING · NA
-
A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo
ACTIVE NOT RECRUITING · NA
-
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
ACTIVE NOT RECRUITING · Early Phase 1
-
Clinical Trial to Evaluate the Efficacy of Skin Products to Improve Skin Quality and Health
COMPLETED · NA
-
Thermage CPT for Treatment of Facial and Neck Laxity
COMPLETED · NA
-
Relationship of Skin Related SNP to Topical Skin Care Product
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia